Government Hosts Sleep Secrets: Join NIH's Circadian Chat
Published Date: 6/11/2025
Notice
Summary
The National Heart, Lung, and Blood Institute is hosting a free, hybrid meeting on August 7-8, 2025, to share updates on sleep and circadian research. Anyone interested in sleep health, researchers, and the public can join in person or online, with registration required. If you want to speak at the meeting, you need to let them know at least 10 days before, so get ready to catch some zzz’s and learn about the latest sleep science!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Free, Hybrid Public Meeting
The Sleep Disorders Research Advisory Board will hold a free, hybrid meeting on August 7, 2025 (1:00 p.m. to 5:00 p.m.) and August 8, 2025 (9:00 a.m. to 2:00 p.m.). The event is open to the public, but separate registration is required for each day and you can watch the meeting via the NIH Videocast link.
Rules To Request To Speak
If you want to present oral comments, you must notify the Contact Person at least 10 days before the meeting and submit a letter of intent, a short description of your organization, and a brief description of your presentation. Only one representative per organization may be allowed to speak, presentations may be limited to five minutes, and both printed and electronic copies are requested for the record.
Submit Written Comments
Anyone may file written comments with the committee by sending a statement to the Contact Person; statements should include name, address, telephone number, and when applicable, business or professional affiliation. Both printed and electronic copies are requested for the record.
Advance Notice For Accommodations
If you plan to attend in person or view the virtual meeting and need special assistance or reasonable accommodations, you should notify the Contact Person listed in the notice in advance of the meeting so the organizers can make arrangements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2025-10537, Applications for New Awards; Gaining Early Awareness and Readiness for Undergraduate Programs (State Grants)
The Department of Education is reopening the GEAR UP State Grants competition for 2025 and extending the application deadline to February 3, 2025. They’re removing some special preference rules to make the process smoother for states applying to help more students get ready for college. If you’re part of a state education team, this is your chance to grab funding and support early college awareness programs!
Next: 2025-10543, Overhead Door Counterbalance Torsion Springs From China and India; Scheduling of the Final Phase of Countervailing Duty and Antidumping Duty Investigations
The U.S. is wrapping up an important investigation to see if imports of overhead door springs from China and India are hurting American businesses. If these springs are found to be unfairly cheap or subsidized, extra taxes might be added to protect U.S. makers. This decision could affect importers, manufacturers, and prices soon.